Golimumab

• Humanized monoclonal antibody targeting TNF
• Indications including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
• Adverse effects include URTI, sinusitis, bronchitis, viral infections (including hepatitis B reactivation), superficial fungal infections, invasive fungal infections, tuberculosis
  • Also elevated ALT, local injection site reactions, hypertension, dizziness, paresthesia, constipation